Tag: M.W=350-400

Kidd, James M. published the artcilePhysical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration, Name: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Clinical Therapeutics (2018), 40(2), 261-269, database is CAplus and MEDLINE.

Meropenem/vaborbactam is a novel i.v. antibiotic combining the carbapenem, meropenem, with a novel β-lactamase inhibitor, vaborbactam. Meropenem/vaborbactam is administered as a 3-h infusion given every 8 h, thereby potentially restricting an i.v. line for 9 h/d. I.v. medications may be given concurrently via Y-site when compatibility data are available. Herein, phys. compatibility was determined for the identification which medications can be coadministered with meropenem/vaborbactam via Y-site.Y-site administration was simulated in vitro by admixing 5 mL of meropenem 8 mg/mL and vaborbactam 8 mg/mL with an equal volume of 88 other diluted i.v. medications, including 34 antimicrobials. All other medications were diluted with 0.9% sodium chloride to the upper range of concentrations considered standard for i.v. infusion. Visual inspection, turbidity measurement, and pH measurement were performed prior to admixture, directly after admixture, and at time points up to 3 h after admixtureOf the 88 medications tested, meropenem/vaborbactam was compatible with 73 (83%), including many antibiotics such as aminoglycosides (amikacin, gentamicin, and tobramycin), colistin, fosfomycin, linezolid, tedizolid, tigecycline, and vancomycin. Phys. incompatibility was observed with albumin, amiodarone, anidulafungin, calcium chloride, caspofungin, ceftaroline, ciprofloxacin, daptomycin, diphenhydramine, dobutamine, isavuconazole, midazolam, nicardipine, ondansetron, and phenytoin.The majority of i.v. medications tested were found to be phys. compatible with meropenem/vaborbactam. These data will help pharmacists and nurses to improve line access in patients receiving meropenem/vaborbactam.

Clinical Therapeutics published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Name: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Asempa, Tomefa E. published the artcilePhysical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration, Safety of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is American Journal of Health-System Pharmacy (2018), 75(14), 1048-1056, database is CAplus and MEDLINE.

The results of a study to determine the phys. compatibility of plazomicin sulfate solution during simulated Y-site administration with 92 i.v. drugs are reported. Plazomicin injection solution (500 mg/10 mL) was diluted in 0.9% sodium chloride or 5% dextrose for injection to a final volume of 50 mL (final plazomicin concentration, 24 mg/mL), consistent with a 15-mg/kg dose administered to an 80-kg patient (i.e., 1,200 mg). All other i.v. drugs were reconstituted according to manufacturers’ recommenda- tions and diluted with 0.9% sodium chloride or 5% dextrose for injection to the upper range of concentrations used clin. Y-site conditions were simulated by mixing 5 mL of plazomicin solution with 5 mL of tested drug solutions in a 1:1 ratio. Solutions were assessed for visual (via color and Tyndall beam testing), turbidity (using a laboratory-grade turbidimeter), and pH changes over a 60-min observation period. Incompatibility was defined a priori as precipitation, color change, a pos. Tyndall test, or a turbidity change of â‰?.5 nephelometric turbidity units at any time during the 60-min observation period. Plazomicin was phys. compatible with 79 of the 92 drugs tested. Determinations of phys. incompatibility with plazomicin were made for 13 drugs: albumin, amiodarone, amphotericin B deoxycholate, anidulafungin, calcium chloride, daptomycin, esomeprazole, heparin, le- vofloxacin, methylprednisolone, micafungin, phenytoin, and propofol, Conclusion. Plazomicin at a concentration of 24 mg/mL was phys. compatible with 85% of the drugs tested, including 31 of 36 antimicrobial agents.

American Journal of Health-System Pharmacy published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Safety of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Markovic, Nov published the artcilePhysical and thermal characterization of chiral omeprazole sodium salts, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Journal of Pharmaceutical and Biomedical Analysis (2006), 42(1), 25-31, database is CAplus and MEDLINE.

The phys. properties of drug substances may affect stability, manufacturing, dissolution and bioavailability. Variations in the degree of crystallinity in a pharmaceutical substance may exhibit physicochem. differences that impact at therapeutic, manufacturing, com. and legal levels, yet no reference has been found on the phys. properties of micronized omeprazole. This study reports on the phys. and thermal characterization of the sodium salts of S- and R-omeprazole, using diffuse reflectance IR Fourier transform spectroscopy (DRIFT), SEM, differential scanning calorimetry (DSC), microthermal anal. (μTA) and powder x-ray diffraction (XRPD). DSC experiments were performed in order to determine not only their thermal stability, but also the thermal history of both forms. SEM results indicate similar morphol., particle size and shape of powd. drug, while, μTA of processed disks shows different topog. images for S- and R-omeprazole, exhibiting a smoother surface for the S-form, indicative of the smoother particle size not evident in the SEM results. The low level of crystallinity of both enantiomers was confirmed by DRIFT spectroscopy and XRPD. Thermal stability by DSC of S- and R-omeprazole sodium salts was superior to that of the neutral omeprazole. This study has examined the phys. and thermal properties of both forms and in highlighting their differences provides an explanation for the potential differences in bioavailability and therapeutic efficacy.

Journal of Pharmaceutical and Biomedical Analysis published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem